Citations

Clear

4847 citation(s) found for "Yu, Eric".

Predictors for survival after radium-223 (R223) treatment for castration-resistant metastatic prostate cancer.
Anderson, Eric, Wong, William W. , Mohammadi, Homan , Daniels, T.B., Tzou, Katherine S., Keole, Sameer R., Choo, Richard , Vora, Sujay A., Schild, Steven E. , Bryce, Alan H. , Ho, Thai H. , Quevedo, Fernando

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e16521-e16521

10.1200/jco.2016.34.15_suppl.e16521 Get It

Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
Adams, Sylvia , Toppmeyer, Deborah , Cescon, David W. , Laurentiis, Michele De, Nanda, Rita , Mukai, Hirofumi , Tamura, Kenji , Liu, Minetta C. , Ryvo, Larisa, Card, Deborah, Ding, Yu , Karantza, Vassiliki , Schmid, Peter , Loi, Sherene , Laurentiis, Michele De, Winer, Eric P. , Armstrong, Anne Caroline , Iwata, Hiroji , Wimberger, Pauline

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 1088-1088

10.1200/jco.2017.35.15_suppl.1088 Get It

1088 Background: Standard first-line treatment for mTNBC is chemotherapy. However, outcomes are poor, and new treatment options are needed. Cohort B of KEYNOTE-086 (NCT02447003) assessed the safety and antitumor activity of pembrolizumab as first-line therapy for patients (pts) with PD-L1–positive mTNBC. Methods: Men and women with centrally confirmed mTNBC, no prior systemic anticancer therapy for metastatic disease, ECOG PS 0-1, and a tumor PD-L1 combined positive score (CPS) ≥1% received pembrolizumab 200 mg Q3W for 24 mo or until disease progression, intolerable toxicity, or investigator or pt decision. Tumor imaging was performed Q9W for 12 mo and Q12W thereafter. Clinically stable pts with PD could remain on pembrolizumab until PD was confirmed on subsequent assessment. Primary end point was safety. Secondary end points included ORR, DOR, and PFS (RECIST v1.1, central review). Planned enrollment was 80 pts. This analysis included all pts who had ≥18 wk of follow-up as of Nov 10, 2016. Results: 79 of the first 137 pts with PD-L1–evaluable tumors (58%) had PD-L1 CPS ≥1%. Of the first 52 pts enrolled, 100% were women, median age was 53 y, 40% had elevated LDH, 69% had visceral metastases, and 87% received prior (neo)adjuvant therapy. After a median follow-up of 7.0 mo (range 4.4-12.5), 15 (29%) pts remained on pembrolizumab. Treatment-related AEs occurred in 37 (71%) pts, most commonly fatigue (31%), nausea (15%), and diarrhea (13%). 4 (8%) pts experienced 5 grade 3-4 treatment-related AEs: back pain, fatigue, hyponatremia, hypotension, and migraine (n = 1 each). No pts died or discontinued pembrolizumab due to an AE. ORR was 23% (95% CI 14%-36%). Best overall response was CR in 4%, PR in 19%, SD in 17%, PD in 58%, and not assessed in 2%. Median time to response was 8.7 wk (range 8.1-17.7). Median DOR was 8.4 mo (range, 2.1+ to 8.4), with 8 (67%) responses ongoing at cutoff. Median PFS was 2.1 mo (95% CI, 2.0-3.9); estimated 6-mo PFS rate was 29%. Conclusions: Data from the first 52 pts enrolled in KEYNOTE-086 cohort B suggest that pembrolizumab monotherapy has a manageable safety profile and promising antitumor activity as first-line therapy for PD-L1–positive mTNBC. Clinical trial information: NCT02447003.
Protein modeling and clinical description of a novel in‐frame GLB1 deletion causing GM1 gangliosidosis type II
Richter, John E. , Zimmermann, Michael T. , Blackburn, Patrick R. , Mohammad, Ahmed N. , Klee, Eric W. , Pollard, Laura, Macmurdo, Colleen, Atwal, Paldeep S. , Caulfield, Thomas R. , Atwal, Paldeep S , Caulfield, Thomas R , Zimmermann, Michael T

Mayo Clinic

Molecular Genetics & Genomic Medicine | September 6, 2018 | Volume: 6 | Issue: 6 | Pages: 1229-1235

10.1002/mgg3.454 | PMID 30187681 Get It

AbstractBackgroundBeta‐galactosidase‐1 (GLB1) is a lysosomal hydrolase that is responsible for breaking down specific glycoconjugates, particularly GM1 (monosialotetrahexosylganglioside). Pathogenic variants in GLB1 cause two different lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB. In GM1 gangliosidosis, decreased β‐galactosidase‐1 enzymatic activity leads to the accumulation of GM1 gangliosides, predominantly within the CNS. We present a 22‐month‐old proband with GM1 gangliosidosis type II (late‐infantile form) in whom a novel homozygous in‐frame deletion (c.1468_1470delAAC, p.Asn490del) in GLB1 was detected.MethodsWe used an experimental protein structure of β‐galactosidase‐1 to generate a model of the p.Asn490del mutant and performed molecular dynamic simulations to determine whether this mutation leads to altered ligand positioning compared to the wild‐type protein. In addition, residual mutant enzyme activity in patient leukocytes was evaluated using a fluorometric assay.ResultsMolecular dynamics simulations showed the deletion to alter the catalytic site leading to misalignment of the catalytic residues and loss of collective motion within the model. We predict this misalignment will lead to impaired catalysis of β‐galactosidase‐1 substrates. Enzyme assays confirmed diminished GLB1 enzymatic activity (~3% of normal activity) in the proband.ConclusionsWe have described a novel, pathogenic in‐frame deletion of GLB1 in a patient with GM1 gangliosidosis type II.
Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.
Maddala, Tara, Aravanis, Alex, Beausang, John F., Filippova, Darya , Gross, Samuel, Jamshidi, Arash , Shen, Ling , Valouev, Anton, Venn, Oliver, Yeatman, Timothy J. , Tibshirani, Robert , Williams, Richard T. , Hartman, Anne‐Renee , Seiden, Michael V., Liu, Minetta C. , Klein, Eric A. , Hubbell, Earl , Aravanis, Alexander M. , Gross, Samuel, Kurtzman, Kathryn N. , Zhang, Nan , Smith, David A. B.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 12021-12021

10.1200/jco.2018.36.15_suppl.12021 Get It

Clinical outcomes after fractional flow reserve-guided treatment of oncology patients.
Dayah, Tariq, Balanescu, Dinu Valentin , Karimzad, Kaveh , Boone, David L., Kim, Peter , Durand, Jean‐Bernard , Herrmann, Joerg , Marmagkiolis, Konstantinos , Johnson, Nils P. , Iliescu, Cezar , Balanescu, Dinu V , Donisan, Teodora , Boone, David L, Lopez‐Mattei, Juan , Yang, Eric H.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e22106-e22106

10.1200/jco.2018.36.15_suppl.e22106 Get It

Symptom burden and employment status in breast cancer (BC) survivors.
Luis, Inês Maria Vaz Duarte, O’Neill, Anne, Sepucha, Karen , Dang, Chau T. , Northfelt, Donald W. , Schneider, Bryan P. , Miller, Kathy D. , Winer, Eric P. , Sledge, George W. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 10073-10073

10.1200/jco.2018.36.15_suppl.10073 Get It

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
Lekakis, Lazaros J. , Jacobson, Caron A. , Jacobsen, Eric D. , Braunschweig, Ira , Oluwole, Olalekan O. , Deol, Abhinav , Bot, Adrian , Rossi, John M. , Jiang, Yizhou , Xue, Allen , Go, William Y., Neelapu, Sattva S. , Oluwole, Olalekan O , Locke, Frederick L. , Ghobadi, Armin , Miklos, David B. , Siddiqi, Tanya , Lin, Yi , Reagan, Patrick Michael , Farooq, Umar

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3039-3039

10.1200/jco.2018.36.15_suppl.3039 Get It